Technology company Danaher Corporation (NYSE: DHR) Tuesday announced financial results for the third quarter of 2023, reporting lower sales and net profit. Third-quarter
Danaher Corp.
-(DHR)
XNYS:DHR
Earnings: Danaher Corporation (DHR) Q2 2023 sales and profit decline
Technology company Danaher Corporation (NYSE: DHR) reported lower sales and net profit for the second quarter of 2023. Second-quarter net income was $1.11
Earnings: Danaher Corporation (DHR) Q1 2023 sales and profit decline
Danaher Corporation (NYSE: DHR), a provider of industrial and medical products, reported lower sales and net profit for the first quarter of 2023. The
Earnings Infographic: Highlights of Danaher Corporation’s (DHR) Q4 results
Danaher Corporation (NYSE: DHR), a provider of industrial and medical products, reported higher sales and net profit for the fourth quarter of 2022. Fourth
Danaher Corp. (DHR) Q3 2020 Earnings Call Transcript
Danaher Corp. (NYSE: DHR) Q3 2020 earnings call dated Oct. 22, 2020 Corporate Participants: Matthew E. Gugino -- Vice President, Investor Relations Rainer M.
Danaher Corp. (DHR) Q2 2020 Earnings Call Transcript
Danaher Corp. (NYSE: DHR) Q2 2020 earnings call dated Jul. 23, 2020 Corporate Participants: Matthew Gugino -- Vice President of Investor Relations Thomas P.
Danaher Corp (NYSE: DHR) Q1 2020 Earnings Call Transcript
Danaher Corp (DHR) Q1 2020 earnings call dated May 07, 2020 Corporate Participants: Matthew E. Gugino -- Vice President of Investor Relations Thomas P.
Danaher Corporation (DHR): Q3 2019 Earnings Snapshot
-- Danaher Corporation (NYSE: DHR) reported Q3 2019 earnings of $1.16 per share, vs. $1.15 expected. -- Revenues grew 4% to $5
10 biggest US mergers & acquisitions announced so far in 2019
We are almost half-way into this year and the M&A market has not disappointed. We have seen a few massive deals so
GE’s stock soars around 15% on news of Biopharma business sale to Danaher
General Electric’s (GE) stock jumped around 15% in premarket hours on Monday after the company announced the sale of its BioPharma business